Global Peripheral Neuropathy Market Industry Overview and Forecast to 2031 - Market Analysis and Market Share

Global Peripheral Neuropathy Market Overview

Peripheral neuropathy is a condition that occurs when the nerves outside of the brain and spinal cord (peripheral nerves) are damaged. The global peripheral neuropathy market is expanding due to rising incidences of diabetes, the leading cause of peripheral neuropathy, and an aging population. For instance, the World Health Organization estimates that over 422 million people globally are affected by diabetes, significantly increasing the prevalence of peripheral neuropathy. Increasing awareness and advancements in diagnostic technologies, such as nerve conduction studies and neuroimaging, are improving early detection and treatment outcomes.

This market report provides details of new recent developments, market share, market trends on the basis of segmentations and regional analysis, impact of market leaders, analysis of the opportunities in terms of emerging revenue pockets, market regulations, strategic market growth analysis, market size, category wise market growths, application niches and dominance, product approvals, product launches, geographic expansions, and technological innovations in the market. To gain more info on the market, contact Data Bridge Market Research’s team of expert analysts. Our team will help you make an informed market decision to achieve market growth.

Global Peripheral Neuropathy Market Size

Advances in diagnostic technologies and innovative treatments are significantly enhancing the management of peripheral neuropathy. Cutting-edge diagnostic tools, such as high-resolution nerve conduction studies and advanced neuroimaging techniques, enable more precise detection and assessment of nerve damage. As a result Databridge Market Research took a dive into comprehensively analyzing the market and unveiled that the Global Peripheral Neuropathy Product Market is increasing at a CAGR of 4.40%. The market size was valued at USD 286.31 million in 2023 and is expected to grow up to USD 404.06 million by 2031.

Global Peripheral Neuropathy Market Dynamics

Global Peripheral Neuropathy Market Growth Drivers

Rise in the cases of Diabetes

The rise in diabetes cases is a major driver of growth in the global peripheral neuropathy market. As diabetes prevalence increases—affecting over 422 million people globally (WHO)—the incidence of peripheral neuropathy, a common complication of the disease, is also on the rise. This growing demand for effective management of nerve damage is spurring advancements in diagnostic technologies and innovative treatments. Consequently, the expanding diabetic population is significantly contributing to the increased need for peripheral neuropathy solutions and driving market growth.

Aging Population

With approximately 1.5 billion people aged 65 and older projected by 2050, age-related conditions, including peripheral neuropathy, are becoming increasingly prevalent. The rising number of elderly individuals intensifies the demand for advanced diagnostic tools and effective treatments tailored to manage and alleviate peripheral neuropathy. Consequently, the healthcare industry is responding to this growing need with innovations and expanded market offerings, further propelling Global Peripheral Neuropathy Market Growth.

Peripheral Neuropathy Market Growth Opportunities

Emergence of innovative diagnostic technologies

The emergence of innovative diagnostic technologies, including high-resolution nerve conduction studies and sophisticated neuroimaging techniques, is creating substantial growth opportunities within the global peripheral neuropathy market. These advancements enable earlier and more precise diagnosis of nerve damage, which improves treatment outcomes and increases demand for specialized care. As a result, healthcare providers are investing more in these technologies, driving global peripheral neuropathy market expansion.

Digital Health Integration

According to the National Institute of Neurological Disorders and Stroke (NINDS), peripheral neuropathy affects approximately 20 million people in the United States alone, but many cases remain undiagnosed due to lack of awareness. Improved awareness has resulted in higher diagnosis rates, with studies indicating that increased education about symptoms and treatment options correlates with a rise in clinical consultations and demand for specialized therapies. This heightened awareness is fueling market expansion by prompting more individuals to seek diagnosis and treatment, thereby driving the growth of peripheral neuropathy-related healthcare products and services.

Peripheral Neuropathy Market Growth Challenges

High Treatment Costs

The expenses associated with advanced diagnostic instruments and cutting-edge therapies for peripheral neuropathy can be considerable, which may hinder accessibility and impact market expansion. For instance, neurostimulation devices, such as the Axon Therapy System, may be priced at over $20,000 per unit, while personalized treatment options, including targeted gene therapies, can surpass $100,000 per patient on an annual basis. Such elevated costs can pose significant challenges for both patients and healthcare systems, especially in areas with constrained healthcare budgets or limited insurance coverage. Consequently, the financial strain may limit patient access to effective treatments and impede overall market development.

Diagnostic Complexity

The nonspecific and overlapping symptoms of peripheral neuropathy, which can mimic other neurological or systemic conditions, contribute to significant diagnostic challenges. For instance, diabetic neuropathy shares symptoms with conditions like carpal tunnel syndrome and multiple sclerosis, complicating accurate diagnosis without extensive testing. This diagnostic complexity not only impacts patient outcomes but also hampers the growth of the global peripheral neuropathy market. Misdiagnoses or delays in treatment can lead to reduced demand for targeted therapies and diagnostic tools, ultimately stunting market expansion and innovation.

Peripheral Neuropathy Market Size Growth Restraints 

Regulatory Complexity acting as a Barrier to Peripheral Neuropathy Market Growth

The growth of the peripheral neuropathy market is also constrained by stringent government regulations, which can delay the approval and commercialization of new therapies and diagnostic tools. Regulatory agencies, such as the FDA in the United States and the EMA in Europe, impose rigorous standards for clinical trials, safety, and efficacy, often leading to extended timelines for product approval. These regulatory hurdles not only increase the cost of bringing new treatments to market but also limit the availability of innovative therapies for patients. Consequently, the market faces challenges in achieving rapid growth, as companies must navigate complex regulatory landscapes that can stifle the development and distribution of essential medical advancements.

Peripheral Neuropathy Market Scope and Trends

• The approval of new extended-release formulations of anti-seizure medications, such as gabapentin and pregabalin, has improved the management of peripheral neuropathy. These formulations provide more consistent pain relief with fewer doses, enhancing patient adherence and treatment outcomes.
• Advances in TENS technology, including more portable and user-friendly devices, have enhanced the accessibility and effectiveness of this therapy. These improvements allow for better pain management at home, making it a more attractive option for patients seeking non-invasive treatment alternatives.
• The rise of digital health technologies and telemedicine has facilitated better homecare management for peripheral neuropathy. Remote monitoring tools and telehealth consultations enable patients to receive ongoing support and adjust their treatments from home, improving overall management and reducing the need for frequent hospital visits.
• The introduction of novel oral medications, such as extended-release formulations of antidepressants and anti-seizure drugs, has provided new options for managing peripheral neuropathy pain. These advancements help maintain consistent therapeutic levels, improving pain control and patient convenience.
• The growth of online pharmacies has made it easier for patients to access peripheral neuropathy medications and treatments. This development has increased the availability of both prescription and over-the-counter products, offering convenience and flexibility for patients managing their condition.

Peripheral Neuropathy Market Regional Analysis – Market Trends

Key Insights

• The U.S. and Canada have supportive regulatory frameworks that facilitate the approval and commercialization of new treatments. The Food and Drug Administration (FDA) and Health Canada are key players in ensuring that novel therapies and diagnostic tools reach the market efficiently.
• European regulatory agencies, such as the European Medicines Agency (EMA), play a crucial role in the approval and commercialization of new therapies. Key European markets, including Germany, France, and the UK, are leading in the adoption of advanced treatments and technologies.
• The high prevalence of diabetes in APAC is a major driver for the peripheral neuropathy market. According to National Library of Medicine (US) the rise of type 2 diabetes in South Asia is estimated to be more than 150% between 2000 and 2035 reflecting robust demand for new treatments and diagnostic solutions.
• The African market faces challenges such as limited healthcare access, variability in treatment availability, and a need for greater awareness about peripheral neuropathy. However, health initiatives (Africa Diabetes Care Initiative) and investments in healthcare infrastructure are driving market growth.

Peripheral Neuropathy Market Leading Players

• Teikoku Pharma USA, Inc (US)
• Sun Pharmaceutical Industries Ltd (India)
• Galen Limited (US)
• Cipher Pharmaceuticals Inc (Canada)
• Mylan N.V. (US)
• Aurobindo Pharma (India)
• Zydus Cadila (India)
• Hikma Pharmaceuticals PLC (UK)
• ACI Limited (Bangladesh)
• Apotex Inc (Canada)
• Johnson & Johnson Services, Inc (US)
• Pfizer Inc (US)
• Arbor Pharmaceuticals (US)
• ALMATICA PHARMA (India)
• Alkem Labs (India)
• Amneal Pharmaceuticals LLC (US)
• Novartis AG (Switzerland)
• Lupin (India)

Global Peripheral Neuropathy Market Recent Developments

• In July 2024, The U.S. Food and Drug Administration (FDA) approved a new extended-release formulation of pregabalin for the treatment of peripheral neuropathy pain. The approval represents a significant advancement in managing chronic neuropathic pain.
• In August 2024, The CMT Research Foundation (CMTRF) has allocated resources to a research initiative located at Nationwide Children’s Hospital in the United States, aimed at creating innovative methods for administering gene therapies to address various forms of Charcot-Marie-Tooth disease (CMT).
• In June, 2024 Ahmedabad-based CORONA Remedies, a pharmaceutical company has set Asia record for screening the highest number of patients for peripheral neuropathy using a biothesiometer in a single week.

DBMR’s market report on the global Peripheral Neuropathy market takes you through valuable insights that can contribute to making several important business decisions. Based on our reports and research expertise you can create realistic growth strategies for your business.

SKU-53041